

Yanling Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1811596/publications.pdf>

Version: 2024-02-01

40
papers

3,113
citations

430442

18
h-index

329751

37
g-index

41
all docs

41
docs citations

41
times ranked

6849
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. <i>Small Methods</i> , 2022, 6, 2100966.	4.6	1
2	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. <i>Cell</i> , 2022, 185, 1389-1401.e18.	13.5	82
3	Characterization of human IgM and IgG repertoires in individuals with chronic HIV-1 infection. <i>Virologica Sinica</i> , 2022, 37, 370-379.	1.2	1
4	The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2022, 11, 1186-1190.	3.0	7
5	A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. <i>Molecular Therapy</i> , 2022, 30, 2785-2799.	3.7	19
6	Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. <i>Viruses</i> , 2022, 14, 1162.	1.5	2
7	Counter changes with changelessness: cope with SARS-CoV-2 immune evasion by targeting cryptic epitopes. , 2022, 1, 24-26.		1
8	A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. <i>MBio</i> , 2022, 13, .	1.8	10
9	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	2.9	110
10	Insights into biological therapeutic strategies for COVID-19. <i>Fundamental Research</i> , 2021, 1, 166-178.	1.6	2
11	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 132.	7.1	29
12	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. <i>Molecules</i> , 2021, 26, 1964.	1.7	4
13	Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. <i>Antibody Therapeutics</i> , 2021, 4, 89-98.	1.2	0
14	Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors. <i>Nano Letters</i> , 2021, 21, 7897-7904.	4.5	64
15	A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. <i>Biomolecules</i> , 2021, 11, 1512.	1.8	12
16	Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay. <i>Journal of the American Chemical Society</i> , 2021, 143, 19794-19801.	6.6	48
17	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
18	Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications. <i>Small Methods</i> , 2020, 4, 2000451.	4.6	5

#	ARTICLE	IF	CITATIONS
19	Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1095-1097.	4.8	168
20	Arming Anti-EGFRvIII CAR-T With TGF β Trap Improves Antitumor Efficacy in Glioma Mouse Models. <i>Frontiers in Oncology</i> , 2020, 10, 1117.	1.3	19
21	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 891-898.e5.	5.1	227
22	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107918.	2.9	148
23	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2020, 9, 382-385.	3.0	1,086
24	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. <i>Cellular and Molecular Immunology</i> , 2020, 17, 765-767.	4.8	564
25	Recent advances in "universal" influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head. <i>Frontiers of Medicine</i> , 2020, 14, 149-159.	1.5	3
26	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	1.5	8
27	A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. <i>PLoS Pathogens</i> , 2019, 15, e1007836.	2.1	32
28	Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice. <i>EBioMedicine</i> , 2019, 49, 247-257.	2.7	11
29	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. <i>Antibodies</i> , 2019, 8, 53.	1.2	8
30	A "sandwich"™ strategy promises functional cure of chronic hepatitis B. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 1-2.	0.4	1
31	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. <i>Aids</i> , 2018, 32, 1749-1761.	1.0	11
32	In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. <i>Frontiers in Immunology</i> , 2018, 9, 128.	2.2	26
33	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017, 22, 471-483.e5.	5.1	48
34	One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. <i>Scientific Reports</i> , 2017, 7, 9130.	1.6	25
35	Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. <i>Scientific Reports</i> , 2017, 7, 6222.	1.6	6
36	Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017, 91, .	1.5	31

#	ARTICLE	IF	CITATIONS
37	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-11.	3.0	41
38	Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding. <i>Frontiers in Immunology</i> , 2017, 8, 1545.	2.2	13
39	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1802.	2.2	78
40	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1469-1478.	1.4	13